Clinical trial
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin…
NCT05282121 · Boehringer Ingelheim, Industry · Terminated
Key facts
| NCT number | NCT05282121 |
|---|---|
| Title | A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) |
| Official title | Randomised, Open-label and Parallel Group Trial to Investigate the Effects of Oral BI 685509 Alone or in Combination With Empagliflozin on Portal Hypertension After 8 Weeks Treatment in Patients With Clinically Significant Portal Hypertension (CSPH) in Compensated Cirrhosis |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Diseases, Hypertension, Portal |
| Intervention type | Drug |
| Interventions | Avenciguat, Empagliflozin |
| Enrollment | 90 |
| Start date | Jun 28, 2022 |
| Primary completion | Apr 23, 2024 |
| Completion | Jun 7, 2024 |
| First posted | Mar 16, 2022 |
| Last update posted | Sep 4, 2025 |
| Countries | Argentina, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Netherlands and 4 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: